Article Text

PDF
A study of the prevalence of vitamin K deficiency in patients with cancer referred to a hospital palliative care team and its association with abnormal haemostasis
  1. D J Harrington1,
  2. H Western2,
  3. C Seton-Jones2,
  4. S Rangarajan1,
  5. T Beynon2,
  6. M J Shearer1
  1. 1
    Centre for Haemostasis and Thrombosis, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  2. 2
    Department of Palliative Care, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  1. Dr Dominic Harrington, Centre for Haemostasis and Thrombosis, 1st Floor, North Wing, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK; domonic.harrington{at}gstt.nhs.uk

Abstract

Background: Many patients with advanced cancer are malnourished. Anorexia is common, as is the use of chemotherapy, which may cause nausea and poor appetite. Ten per cent of these patients experience haemorrhagic events.

Aim: Since vitamin K deficiency (VKD) causes bleeding, to establish the prevalence of VKD in patients with advanced cancer receiving palliative care.

Methods: Serum concentrations of vitamin K1 and undercarboxylated factor II (PIVKA-II) were determined in 46 (17 male/29 female) inpatients aged 26–85 (mean 58) years. INR and liver function tests (bilirubin, ALT, GGT and ALP) were also performed.

Results: Vitamin K1 was below the lower limit of the reference range (0.33 nmol/l) in 22% of patients. 78% of patients had some degree of functional VKD indicated by raised (>0.2 AU/ml) PIVKA-II. Six patients (13%) had a prolonged INR, all of whom had raised PIVKA-II and GGT; 4 also had vitamin K1 <0.33 nmol/l. Three patients (6.5%) had clinically significant VKD characterised by INR >1.5, PIVKA-II >10 AU/ml, and undetectable vitamin K1.

Conclusions: Patients with advanced cancer are prone to VKD which, while usually subclinical, may develop to a clinically relevant prolongation of the INR. Serum measurements of vitamin K1 and PIVKA-II can be used to detect VKD and monitor vitamin K status before an increased risk of bleeding develops.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Ethics approval: Ethics approval was obtained from the Lewisham Ethics Committee.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.